BPC-157 — Research Dossier
Evidence grading
Studies reviewed
36
2025 systematic review — HSS Journal
Preclinical studies
35
Animal or in-vitro — of 36 total
Controlled human trials
0
1 retrospective clinical analysis only
Mechanism (proposed)
Multi-target
VEGF / Egr-1 / TGF-β / fibroblast pathways
BPC-157 is one of the most-studied compounds in preclinical tissue-repair research — and a clear example of a large animal-model literature paired with almost no controlled human data. This dossier catalogues what has and has not been established.
BPC-157 — Body Protection Compound — is a 15-amino-acid synthetic peptide derived from a protective sequence first studied in human gastric juice, in work originating largely with Sikirić and colleagues at the University of Zagreb. It is reported to be stable across a range of pH conditions, which has made it a subject of oral-administration studies in animal models.
“A 2025 systematic review identified 36 relevant studies, of which 35 were preclinical and one was a small retrospective clinical analysis — confirming consistent preclinical signals while highlighting the near-complete absence of human data.”
— Vasireddi N et al., HSS Journal 2025
The preclinical evidence
Across rodent models of tendon transection, ligament injury, muscle laceration and fracture, the literature consistently reports accelerated structural repair and improved functional recovery under controlled experimental conditions.
Mechanistic studies focus on angiogenesis via VEGF-related signalling, fibroblast activation, and collagen synthesis through Egr-1 and TGF-β pathways, alongside a substantial body of gastrointestinal-protection work.
A 2025 systematic review identified 36 relevant studies, of which 35 were preclinical and one was a small retrospective clinical analysis — confirming consistent preclinical signals while highlighting the near-complete absence of human data.
Limitations recorded in the literature
Reviewers note that most studies use a single dose level administered to rodents, which prevents construction of dose–response relationships, and that rodent models carry well-recognised limits in predicting human outcomes for peptides.
BPC-157 is reported to be metabolised hepatically with a half-life under 30 minutes and renal clearance; no controlled clinical safety data are recorded.
Regulatory and status notes
BPC-157 holds no regulatory approval for human use. It was temporarily listed by the World Anti-Doping Agency in 2022 and is not currently listed.
The US FDA has flagged that compounded products containing BPC-157 may carry immune-reaction risks, citing insufficient human safety data.
What this evidence is — and isn’t
These trials studied pharmaceutical-grade BPC-157 administered under medical supervision in controlled settings. The figures summarised in this dossier describe that published science only.
They are not outcomes associated with research-grade material, and not results attributable to any use of the product sold in this catalogue. Nothing here is an endorsement, recommendation, or instruction for human use.
Nexyra Lab Catalogue
This dossier covers published clinical research on BPC-157. Nexyra Lab supplies research-grade BPC-157 for in vitro laboratory use.
View BPC-157 in the Nexyra catalogue (research use only) →References
- 1
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
- 2
Authors not yet confirmed — owner to update. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2025. DOI: 10.3390/pharmaceutics18050625
- 3
Authors not yet confirmed — owner to update. Multifunctionality and Possible Medical Application of the BPC-157 Peptide — Literature and Patent Review. Pharmaceuticals (MDPI). 2025.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.